您当前所在的位置:首页 > 产品中心 > 产品详细信息
82419-36-1 分子结构
点击图片或这里关闭

7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid

ChemBase编号:1036
分子式:C18H20FN3O4
平均质量:361.3675032
单一同位素质量:361.14378436
SMILES和InChIs

SMILES:
Fc1c(N2CCN(CC2)C)c2OCC(n3c2c(c1)c(=O)c(c3)C(=O)O)C
Canonical SMILES:
CN1CCN(CC1)c1c(F)cc2c3c1OCC(n3cc(c2=O)C(=O)O)C
InChI:
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
InChIKey:
GSDSWSVVBLHKDQ-UHFFFAOYSA-N

引用这个纪录

CBID:1036 http://www.chembase.cn/molecule-1036.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
IUPAC传统名
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
ofloxacin
商标名
Akilen
Baccidal
Bactocin
Danoflox
Effexin
Exocin
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxstat
Fugacin
Inoflox
Kinflocin
Kinoxacin
Liflox
Loxinter
Marfloxacin
Medofloxine
Mergexin
Novecin
Nufafloqo
O-Flox
Obide
Occidal
Ofcin
Oflin
Oflocee
Oflocet
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
Ofloxin
Ofus
Onexacin
Operan
Orocin
Otonil
Pharflox
Praxin
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Sinflo
Tabrin
Taravid
Tariflox
Tarivid
Telbit
Tructum
Uro Tarivid
Viotisone
Zanocin
Floxin
别名
氧氟沙星
9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid
Floxil
Monoflocet
Ocuflox
Mefoxacin
Oflocin
Ofloxacin
Oflocet
Ofloxacine
Oxaldin
Tarivid
Visiren
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
Ofloxacin
DL-8280
HOE-280
Exocin
Flobacin
Floxin
CAS号
82419-36-1
MDL号
MFCD00226105
PubChem SID
24278613
160964499
24860450
46507574
PubChem CID
4583

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 5.4470572  质子受体
质子供体 LogD (pH = 5.5) 0.616237 
LogD (pH = 7.4) -0.2825112  Log P 0.65427977 
摩尔折射率 94.9359 cm3 极化性 34.82272 Å3
极化表面积 73.32 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P -0.02  LOG S -2.4 
溶解度 1.44e+00 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
28.3 mg/mL expand 查看数据来源
Chloroform expand 查看数据来源
DMSO expand 查看数据来源
外观
Off-White Solid expand 查看数据来源
熔点
270-275°C expand 查看数据来源
疏水性(logP)
2.1 expand 查看数据来源
保存条件
-20°C expand 查看数据来源
-20°C Freezer expand 查看数据来源
Room Temperature (15-30°C) expand 查看数据来源
RTECS编号
UU8815500 expand 查看数据来源
欧盟危险性物质标志
有害性(Harmful) 有害性(Harmful) (Xn) expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
德国WGK号
2 expand 查看数据来源
危险公开号
R:40-20/21/22-42/43 expand 查看数据来源
安全公开号
S:22-26-45-36/37/39 expand 查看数据来源
个人保护装置
Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter expand 查看数据来源
保存温度
2-8°C expand 查看数据来源
room temp expand 查看数据来源
作用靶点
topoisomerase expand 查看数据来源
相关基因信息
human ... CSNK2A1(1457), KCNH1(3756)rat ... Gabra1(29705) expand 查看数据来源
生物活性机理
DNA gyrase inhibitor expand 查看数据来源
级别
certified reference material expand 查看数据来源
VETRANAL™, analytical standard expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
包装
pkg of 1 g expand 查看数据来源
适用性
suitable for 1694 per US EPA expand 查看数据来源
应用领域
Antibacterial agent expand 查看数据来源
Antiseptic expand 查看数据来源
Shows broad spectrum of activity against gram-positive and -negative bacteria expand 查看数据来源
Pharmacopeia Traceability
traceable to USP 1478108 expand 查看数据来源
Empirical Formula (Hill Notation)
C18H20FN3O4 expand 查看数据来源

详细说明

详细说明

MP Biomedicals MP Biomedicals DrugBank DrugBank Selleck Chemicals Selleck Chemicals Sigma Aldrich Sigma Aldrich TRC TRC
MP Biomedicals -  02199018 external link
Anti-bacterial Agent
DrugBank -  DB01165 external link
Item Information
Drug Groups approved
Description A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]
Indication For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
Pharmacology Ofloxacin is a quinolone/fluoroquinolone antibiotic. Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Toxicity LD50=5450 mg/kg (orally in mice)
Affected Organisms
Enteric bacteria and other eubacteria
Biotransformation Hepatic
Absorption Bioavailability of ofloxacin in the tablet formulation is approximately 98%
Half Life 9 hours
Protein Binding 32%
Elimination Elimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of ofloxacin.
External Links
Wikipedia
RxList
PDRhealth
Drugs.com
Selleck Chemicals -  S1463 external link
Research Area: Infection
Biological Activity:
Ofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase and topoisomerase IV, which is an enzyme necessary to separate replicated DNA, thereby inhibiting cell division. [1]
Sigma Aldrich -  O8757 external link
Other Notes
Nalidixic acid analog with broad-spectrum antibacterial activity.
Application
Ofloxacin is a synthetic fluoroquinolone with broad-spectrum antibacterial activity. It is a nalidixic acid analog. It is given to patients before undergoing retinal reattachment surgery1. It is used to study pneumococcal cell wall-degrading virulence factors2.
Biochem/physiol Actions
Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, which haults DNA replication and cell division. Ofloxacin has been shown to convert LytA from the inactive E-form to the active C-form2. It is a chiral molecule that inhibits pneumococcal cell wall-degrading virulence factors2.
Sigma Aldrich -  33703 external link
法律信息
VETRANAL 商标 Sigma-Aldrich Co. LLC
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. 33703.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.
Sigma Aldrich -  PHR1168 external link
General description
This certified reference material (CRM) is produced and certified in accordance with ISO/IEC 17025 and ISO Guide 34.
Other Notes
Values of analytes vary lot to lot.
Toronto Research Chemicals -  O245750 external link
Fluorinated quinolone antibacterial.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • http://www.rxlist.com/floxin-drug.htm
  • Monk, J.P., et al.: Drugs, 33, 346 (1987)
  • Drlica, K., Curr. Opin. Microbiol. 2, 504 (1990)
  • Sato, K. et al., Antimicrob. Agents Chemother., 1982, 22, 548, (pharmacol)
  • Eur. Pat., 1982, Daiichi Seiyaku, 47 005; CA, 97, 55821b, (synth, pharmacol)
  • Hayakawa, I. et al., Antimicrob. Agents Chemother., 1986, 29, 163, (resoln, props)
  • Egawa, H. et al., Chem. Pharm. Bull., 1986, 34, 4098, (synth)
  • Monk, J.P. et al., Drugs, 1987, 33, 346, (rev)
  • Mitscher, L.A. et al., J. Med. Chem., 1987, 30, 2283, (synth, activity)
  • New Gener. Quinolones, 1990, (Eds. Siporin, C. et al), M. Dekker (see Infect. Dis. Ther. v5 1990), 1990, (book)
  • The 4-Quinolones: Antibacterial Agents in Vitro, (Ed. Crumplin, G.C.), Springer-Verlag, London, 1990, (book)
  • Todd, P.A. et al., Drugs, 1991, 42, 825, (rev)
  • Tunkel, A.R. et al., Infect. Control Hosp. Epidemiol., 1991, 12, 549, (activity, rev)
  • Atarashi, S. et al., J. Het. Chem., 1991, 28, 329, (synth)
  • Sanders, C.C., Clin. Infect. Dis., 1992, 14, 526, (rev)
  • Lamp, K.C. et al., Clin. Pharmacokinet., 1992, 22, 32, (pharmacokinet, rev)
  • Davis, R. et al., Drugs, 1994, 47, 677, (rev)
  • Negwer, M., Organic-Chemical Drugs and their Synonyms, 7th edn., Akademie-Verlag, 1994, 6400; 6401, (synonyms)
  • Hashimoto, K. et al., Acta Cryst. C, 1995, 51, 519
  • Kitaoka, H. et al., Chem. Pharm. Bull., 1995, 43, 649, (cryst struct, props)
  • Langtry, H.D. et al., Drugs, 1998, 56, 487-515; 895-928, (rev)
  • Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 221; 233
  • Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, OGI300
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle